TerminatedPhase 3

Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV

Stopped: Sponsor decision not based on any new unexpected safety findings or efficacy observations.

United States453 participantsStarted 2013-07-11

Plain-language summary

To evaluate Sustained Virologic Response at post treatment Week 12 (SVR12)following treatment with Lambda/RBV/DCV in chronic HCV GT-1, -2, -3 or -4 subjects co-infected with HIV-1

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Mild-factor level activity of 6-4% OR
✓. Moderate defined as factor level activity of 1-5%

What they're measuring

Number of Participants With Sustained Virologic Response at Post-treatment Week 12 (SVR12)

Timeframe: Follow-up week 12

Trial details

NCT IDNCT01866930

SponsorBristol-Myers Squibb

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2015-08-27

Results submitted2019-03-22

View on ClinicalTrials.gov More Chronic Hepatitis C Infection trials